Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...

CEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven primarily by hematology sales, and an adjusted EBITDA margin of 34%. He noted strong demand for Altuvoct and Vonjo, with Altuvoct ...

Shares of Swedish Orphan Biovitrum AB (STO:SOBI) fell 3% as the company's fourth-quarter earnings report revealed mixed results. While overall Q4 revenue met consensus expectations, sales of its key ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024. Fourth Quarter 2024 Total revenue increased ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024. Fourth Quarter ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.